Canola oil may tame metabolic syndrome, study hints
NCT ID NCT01890330
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at whether eating canola oil every day for 12 weeks can improve cholesterol, blood vessel function, and other risk factors in people with metabolic syndrome. Eighty adults with the condition were randomly assigned to consume either canola oil or a typical Western fat blend. Researchers measured changes in blood fats and artery health to see if canola oil offers any advantage.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Canola oil
- What this could lead to
- If it works, this could point toward a simple dietary change to help manage metabolic syndrome and reduce heart disease risk.
- What could go wrong
- This is a small, early-stage dietary study with only 80 participants. Results may not apply to everyone, and any benefits are likely modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
80 people
The number who actually took part.
- Start date
-
Jul 2013
- Finished
-
Mar 2016
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male, or non-pregnant, non-lactating females, aged 20 - 75 years; 2. LDL-Cholesterol \>2.5 mmol/L and \<5.0 mmol/L 3. If the participant has 2 or more of the following characteristics of MetS * Fasting blood glucose \>5.6 mmol/L and \<7.0 mmol/L; * Blood pressure \>130/85 mm Hg and \<150/100; * Triglycerides \>1.7 mmol/L and \<4.0 mmol/L; * HDL-cholesterol \<1.0 mmol/L in males or \<1.3 mmol/L in females; * Abdominal obesity as defined by a waist circumference of \>102 cm (40 inches) in males and \>88 cm (35 inches) in females of non-Asian ethnicity, and a waist circumference of \>94 cm (37 inches) in males and \>80 cm (32 inches) in females of Asian ethnicity. 4. Able to read, write and communicate orally in English; 5. Willing to maintain a stable level of activity during participation in the study; 6. Willing to maintain dietary routine, refrain from consuming omega-3 supplements or omega-3 rich foods (\>0.3 grams ALA/serving or, \>0.1 grams of EPA and DHA; see handout with examples) and refrain from taking any over-the-counter medications or herbal supplements specified for weight loss, or the lowering of blood lipids, blood glucose or blood pressure from acceptance into the study until the final study visit; 7. Willing to comply with protocol requirements and procedures; 8. Willing to provide written informed consent. Exclusion Criteria: 1. Use of prescribed medications for lowering or managing blood lipids (hyperlipidemia), blood glucose (hyper/hypoglycemia), blood pressure (hypertension) or body weight; 2. Regular use of non-prescription products, over-the-counter medications, or herbal supplements designed to lower blood lipids, blood glucose, blood pressure or body weight, or omega-3 supplements or omega-3 rich foods, within the past 3 months; 3. Participating in or adhering to a weight loss diet or physical activity program designed to facilitate weight loss. 4. Adhering to a physician or dietitian directed lifestyle or dietary modification program for the purpose of lowering hypercholesterolemia; 5. Medical history of liver disease, with the exception of fatty liver, or chronic renal disease; 5\. Any acute medical condition or surgical intervention within the past 3 months; 6. Conditions or medications which are likely to increase the risk to the participants or study personnel, or to reduce the ability of the participant to comply with the protocol, or affect the results; 7. History of gastrointestinal reactions or allergies to canola oil or to one or more ingredients in the study foods which significantly limits the number of study foods that can be consumed; and 8. Currently participating in or having participated in a food intervention study within the last 3 months.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metabolic syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
St. Boniface General Hospital - I.H. Asper Clinical Research Institute
Winnipeg, Manitoba, R2H 2A6, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which exercise dose best helps kids with metabolic syndrome?
- Can a weekly weight drug quiet gout attacks?
- Can a Once-Daily form of tacrolimus spare liver transplant patients from side effects?
- Ketogenic diet vs mediterranean diet: which better reshapes metabolism?
- Can tailoring bypass length improve weight loss surgery results?
- Can AI predict your lifespan from a short video?